Aethlon Medical, Inc. (AEMD) Financial Ratios
30 years of historical data (1997–2026) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.26
↓-94% vs avg
5yr avg: 4.26
30Y Low0.3·High59.9
ROE
↓
-142.9%
-8% vs avg
5yr avg: -132.1%
30Y Low-452%·High-65%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
AEMD Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Aethlon Medical, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1M | $1M | $4M | $34M | $62M | $172M | $196M | $42M | $138M | $117M | $203M |
| Enterprise Value | $-3250919 | $-3213800 | $-387508 | $29M | $49M | $156M | $187M | $32M | $135M | $111M | $202M |
| P/E Ratio → | -0.18 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | 108.74 | 586.05 | 297.89 | 63.86 | 599.87 | 783.65 | 518.03 |
| P/B Ratio | 0.26 | 0.30 | 0.87 | 5.86 | 4.15 | 10.15 | 21.13 | 4.48 | 59.91 | 19.44 | 341.13 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
AEMD EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | 85.53 | 530.50 | 282.99 | 49.31 | 587.39 | 742.66 | 515.38 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
AEMD Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -142.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | -1242674.4% | -1661027.2% | -787423.3% |
| Operating Margin | — | — | — | — | -2072.0% | -3542.5% | -1197.3% | -912.0% | -2612.5% | -3228.7% | -1555.3% |
| Net Profit Margin | — | — | — | — | -2094.9% | -3540.9% | -1196.6% | -980.3% | -2697.9% | -3796.2% | -1855.8% |
Return on Capital
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -142.9% | -142.9% | -245.9% | -117.2% | -75.1% | -79.3% | -84.9% | -110.1% | -148.7% | -171.4% | -693.7% |
| ROA | -104.5% | -104.5% | -171.6% | -94.8% | -65.2% | -69.2% | -74.9% | -87.9% | -108.0% | -125.1% | -339.8% |
| ROIC | -2334.9% | -2334.9% | -911.8% | -630.8% | -747.2% | -12703.3% | — | — | — | — | — |
| ROCE | -141.0% | -141.0% | -157.3% | -112.7% | -70.8% | -77.5% | -84.8% | -102.1% | -130.8% | -120.9% | -387.8% |
AEMD Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $5M exceeds total debt of $336718, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.13 | 0.16 | 0.08 | 0.04 | 0.00 | 0.02 | 0.42 | 0.14 | 0.87 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.96 | -0.95 | -0.78 | -0.88 | -0.96 | -1.06 | -1.02 | -1.25 | -1.02 | -1.75 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -496.60 | -496.60 | -1323.37 | — | — | — | -4994.62 | -109.34 | -27.21 | -14.76 | -23.01 |
Net cash position: cash ($5M) exceeds total debt ($336718)
AEMD Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Aethlon Medical, Inc.'s current ratio of 3.85x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 3.40x to 3.85x over the past 3 years.
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.85 | 3.85 | 3.13 | 3.40 | 10.03 | 9.95 | 7.53 | 9.40 | 2.21 | 15.13 | 2.61 |
| Quick Ratio | 3.85 | 3.85 | 3.13 | 3.40 | 10.03 | 9.95 | 7.53 | 9.40 | 2.21 | 15.13 | 2.61 |
| Cash Ratio | 3.47 | 3.47 | 2.90 | 2.97 | 9.66 | 9.36 | 7.17 | 9.00 | 2.10 | 14.59 | 2.55 |
| Asset Turnover | — | — | — | — | 0.03 | 0.02 | 0.06 | 0.06 | 0.06 | 0.02 | 0.23 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | 158.78 | 82.56 | 116.05 | — | 182.50 | — |
AEMD Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Aethlon Medical, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.2% | 0.2% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.2% | 0.2% |
| Shares Outstanding | — | $673945 | $156084 | $251300 | $205400 | $147600 | $120900 | $34148 | $12083 | $8211 | $5176 |
Peer Comparison
Compare AEMD with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 AEMDYou | $1M | -0.2 | — | — | — | — | -142.9% | -2334.9% | — |
 XTLB | $279464 | -0.3 | — | — | 0.7% | -481.6% | -26.8% | -54.1% | — |
 EKSO | $57M | -4.8 | — | — | 53.5% | -104.1% | -107.6% | -88.1% | — |
 PRTH | $590M | 10.5 | 7.6 | 7.9 | 21.4% | 14.8% | — | 13.4% | 5.1 |
 TELA | $37M | -1.0 | — | — | 67.7% | -42.0% | -223.4% | -169.0% | — |
 BAX | $10B | -11.4 | 27.2 | 31.8 | 30.1% | -2.7% | -14.6% | -1.4% | 14.9 |
 NVCR | $2B | -11.7 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 ITGR | $3B | 31.5 | 13.5 | 29.8 | 23.1% | 11.3% | 6.1% | 5.4% | 4.2 |
 MMSI | $4B | 31.6 | 14.0 | 18.6 | 48.7% | 12.2% | 8.7% | 7.2% | 2.8 |
 ICUI | $4B | 4774.5 | 14.1 | 38.2 | 36.8% | 4.8% | 0.0% | 2.5% | 4.3 |
 ATRC | $1B | -120.0 | 80.7 | 30.2 | 74.4% | -0.6% | -2.4% | -0.6% | 5.2 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
AEMD — Frequently Asked Questions
Quick answers to the most common questions about buying AEMD stock.
What is Aethlon Medical, Inc.'s P/E ratio?
Aethlon Medical, Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
What is Aethlon Medical, Inc.'s ROE?
Aethlon Medical, Inc.'s return on equity (ROE) is -142.9%. The historical average is -153.9%.
Is AEMD stock overvalued?
Based on historical data, Aethlon Medical, Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.